RNA Stock Summary and Trading Ideas (Atrium Therapeutics | NASDAQ:RNA)

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Atrium Therapeutics trades on the NASDAQ stock market under the symbol RNA.

As of August 20, 2026, RNA stock price declined to $13.48 with 205,490 million shares trading.

RNA has a beta of 1.57, meaning it tends to be more sensitive to market movements. RNA has a correlation of 0.01 to the broad based SPY ETF.

RNA has a market cap of $230.58 million. This is considered a Small Cap stock.

Last quarter Atrium Therapeutics reported $3 million in Revenue and -$1.18 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.41.

In the last 3 years, RNA traded as high as $73.06 and as low as $4.83.

The top ETF exchange traded funds that RNA belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.

RNA has underperformed the market in the last year with a return of -69.4%, while the SPY ETF gained +20.4%. In the last 3 month period, RNA fell short of the market, returning +4.1%, while SPY returned +4.2%. However, in the most recent 2 weeks RNA has outperformed the stock market by returning +14.8%, while SPY returned -0.9%.

RNA support price is $13.35 and resistance is $14.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNA shares will trade within this expected range on the day.